Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ.

Am J Surg Pathol. 2011 Oct;35(10):1549-56. doi: 10.1097/PAS.0b013e31822895e5.

2.

Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.

Chaux A, Albadine R, Schultz L, Hicks J, Carducci MA, Argani P, Allaf M, Netto GJ.

Hum Pathol. 2013 Oct;44(10):2323-30. doi: 10.1016/j.humpath.2013.05.014. Epub 2013 Aug 15.

PMID:
23953228
3.

Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ.

Hum Pathol. 2012 Dec;43(12):2129-37. doi: 10.1016/j.humpath.2012.01.009. Epub 2012 Apr 26.

4.

Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.

Munari E, Fujita K, Faraj S, Chaux A, Gonzalez-Roibon N, Hicks J, Meeker A, Nonomura N, Netto GJ.

Hum Pathol. 2013 Dec;44(12):2668-76. doi: 10.1016/j.humpath.2013.07.008. Epub 2013 Sep 27.

PMID:
24074531
5.

Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.

Nishikawa M, Miyake H, Harada K, Fujisawa M.

Urol Oncol. 2014 Jan;32(1):49.e15-21. doi: 10.1016/j.urolonc.2013.07.014. Epub 2013 Nov 13.

PMID:
24239474
6.

Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.

Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V.

Cancer. 2015 Jan 1;121(1):43-50. doi: 10.1002/cncr.28976. Epub 2014 Sep 3.

7.

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.

Cancer. 2007 Jun 1;109(11):2257-67.

8.

Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.

Stoyanoff TR, Rodríguez JP, Todaro JS, Espada JD, Colavita JP, Brandan NC, Torres AM, Aguirre MV.

Tumour Biol. 2016 Oct;37(10):13581-13593. Epub 2016 Jul 28.

PMID:
27468719
9.

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Szendrői A, Szász AM, Kardos M, Tőkés AM, Idan R, Szűcs M, Kulka J, Nyirády P, Szendrői M, Szállási Z, Győrffy B, Tímár J.

Oncotarget. 2016 Jul 5;7(27):42086-42098. doi: 10.18632/oncotarget.9669.

10.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.

White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM.

Br J Cancer. 2014 Mar 4;110(5):1250-9. doi: 10.1038/bjc.2013.828. Epub 2014 Feb 4.

11.
12.

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Clin Cancer Res. 2007 Dec 15;13(24):7388-93.

13.

Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.

Faraj SF, Albadine R, Chaux A, Gonzalez-Roibon N, Hicks J, Humphreys E, Partin A, Netto GJ.

Urology. 2013 Nov;82(5):1083-9. doi: 10.1016/j.urology.2013.07.028. Epub 2013 Sep 11.

PMID:
24035134
14.

Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.

Ji SQ, Su XL, Cheng WL, Zhang HJ, Zhao YQ, Han ZX.

Urol Oncol. 2014 Feb;32(2):153-61. doi: 10.1016/j.urolonc.2012.09.013. Epub 2012 Dec 27.

PMID:
23273913
15.

Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.

Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, Montironi R, Muzzonigro G.

Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):447-55.

PMID:
18547492
17.

Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma.

Darwish OM, Kapur P, Youssef RF, Bagrodia A, Belsante M, Alhalabi F, Sagalowsky AI, Lotan Y, Margulis V.

Urology. 2013 Mar;81(3):581-6. doi: 10.1016/j.urology.2012.11.030. Epub 2013 Jan 3.

PMID:
23290145
18.

Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.

Oz Atalay F, Aytac Vuruskan B, Vuruskan H.

APMIS. 2016 Apr;124(4):257-62. doi: 10.1111/apm.12499. Epub 2016 Jan 11.

PMID:
26750935
19.

Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Nielsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ.

Cancer. 2010 Dec 1;116(23):5517-26. doi: 10.1002/cncr.25502. Epub 2010 Oct 11. Erratum in: Cancer. 2011 Nov 1;117(21):5021. Neilsen, Matthew E [corrected to Nielsen, Matthew E].

20.

Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.

Tóth K, Chintala S, Rustum YM.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):642-7. doi: 10.1097/PAI.0000000000000012.

Supplemental Content

Support Center